Literature DB >> 16273073

Activation of the mammalian immune system by siRNAs.

Joao T Marques1, Bryan R G Williams.   

Abstract

Inhibition of gene expression through RNA interference (RNAi) is emerging as a powerful experimental tool for gene function and target validation studies. The potential uses of this technology seem unlimited, extending to the prevention and therapy of human diseases. However, recent work demonstrating that there are unanticipated, different nonspecific effects associated with the use of small interfering RNAs in mammals has raised concerns about the safe use of RNAi in vivo. These nonspecific effects include activation of the immune system, potentially harming the individual. The application of screening assays for nonspecific activation of both innate and acquired immunity will be necessary for further development of RNAi as a therapeutic tool.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273073     DOI: 10.1038/nbt1161

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  108 in total

Review 1.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

2.  Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA.

Authors:  Sandesh Subramanya; Myriam Armant; Janelle R Salkowitz; Alice M Nyakeriga; Viraga Haridas; Maroof Hasan; Anju Bansal; Paul A Goepfert; Katherine K Wynn; Kristin Ladell; David A Price; Manjunath N; June Kan-Mitchell; Premlata Shankar
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

Review 3.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 4.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 5.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

6.  Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Authors:  Arvind Chhabra; Nitya G Chakraborty; Bijay Mukherji
Journal:  Clin Immunol       Date:  2008-01-14       Impact factor: 3.969

7.  Promiscuous 8-alkoxyadenosines in the guide strand of an siRNA: modulation of silencing efficacy and off-pathway protein binding.

Authors:  Uday Ghanty; Erik Fostvedt; Rachel Valenzuela; Peter A Beal; Cynthia J Burrows
Journal:  J Am Chem Soc       Date:  2012-10-11       Impact factor: 15.419

8.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

Review 9.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

10.  Nanotubes functionalized with lipids and natural amino acid dendrimers: a new strategy to create nanomaterials for delivering systemic RNAi.

Authors:  Joshua McCarroll; Huricha Baigude; Chao-Shun Yang; Tariq M Rana
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.